ライフサイエンスコーパス: RTV

1 RTV is responsible for the adverse interactions that occ

2 and terrestrial applications namely RTV 655, RTV 615, and Sylgard 184.

3 s C virus (HCV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) antiretroviral regimen (300

4 ants were followed in subjects who had added RTV to their previously failed reverse transcriptase inh

5 After RTV was withdrawn, the TVR AUC(0-12) (area under the con

6 3 and 0.09 mg/dL, respectively, for COBI and RTV recipients.

7 r 95% entrapment efficiency for both LPV and RTV and stability over 8h in simulated physiological con

8 B subjects receiving GSK3532795 and ATV +/- RTV achieved similar declines to those receiving SOC.

9 ainst subtype B (monotherapy or with ATV +/- RTV) and subtype C, and was generally well tolerated, wh

10 otease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

11 marate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.

12 erapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-t

13 ned (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered once da

14 function tests than did those receiving ATV/RTV+FTC/TDF and had smaller median increases in fasting

15 Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virologic

16 Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks.

17 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome (316 patients [89.5%

18 udy, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subjects

19 (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

20 d EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+

21 l midline cortex is strongly related to both RTV and ADHD, both phenotypically and genetically.

22 Dissolution of an ASD containing RTV, ATV and lopinavir (LPV) was also investigated.

23 Coadministration with boceprevir decreased RTV AUC during a dosing interval tau (AUC(tau)) by 22%-3

24 creased and a similar trend was observed for RTV.

25 ary sites, as compared to the commercial LPV/RTV tablet (Kaletra(R)) in rats.

26 Furthermore, LPV/RTV ISNP granules displayed a 2.56-fold increase in bioa

27 or space and terrestrial applications namely RTV 655, RTV 615, and Sylgard 184.

28 SNP granules with about 16% of LPV and 4% of RTV were palatable and stable at room temperature over 6

29 erse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events leading to discontinu

30 chieved in 85% of COBI recipients and 87% of RTV recipients (difference, -2.2% [95% confidence interv

31 tically related neurophysiological marker of RTV in ADHD.

32 formulation containing a 1:1 molar ratio of RTV and ATV achieved only 50% of the supersaturation att

33 dispersion containing a 1:1:1 molar ratio of RTV, ATV and LPV, the maximum concentration of each drug

34 Our aim was to evaluate the role of RTV in the bidirectional TVR and atazanavir (ATV) intera

35 Effect of ultraviolet radiation on RTV 655 was also investigated and compared with the effe

36 ect of TVR on ATV exposure is higher than on RTV, despite its shorter terminal half-life.

37 en event-related midline theta oscillations, RTV, and ADHD.

38 tudy (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC).

39 ects were treated in this study (155 to PI + RTV + FTC/TDF, 156 to PI + RTV + 3TC/ABC).

40 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvi

41 bserved when telaprevir (TVR) and ritonavir (RTV)-boosted human immunodeficiency virus (HIV) protease

42 istance to the protease inhibitor ritonavir (RTV) in vivo.

43 d a fixed-dose combination of LPV/ritonavir (RTV) ISNP granules, were prepared using the ISNP nanotec

44 Subjects receiving 3TC/ABC + PI + ritonavir (RTV) with HIV-1 RNA < 200 c/mL >/=3 months were randomiz

45 fficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combin

46 RV) 600 mg twice daily, each with ritonavir (RTV) 100 mg on days 10-31, plus concomitant boceprevir o

47 navir (ATV) with or without (+/-) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fum

48 n was then fabricated from 10 mL of silicone RTV catalyst mixed with 1 mL of base and 50 mg of CaF2:E

49 were studied: (1) the plasticized PVC or SR (RTV 3140) membrane matrix without other added membrane c

50 onship between the cognitive control system, RTV, and ADHD is unknown.

51 dy drug (344 in the COBI group vs 348 in the RTV group).

52 the rate of turnover of pro variants in the RTV-treated subjects we estimated that the mean fitness

53 used damage and significant discoloration to RTV 655.

54 COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48.

55 ation capacity and reduced susceptibility to RTV.

56 Reaction time variability (RTV) is consistently increased in ADHD and is known to s

57 gs compared with their coadministration with RTV.